Tonghua Dongbao Pharmaceutical Co., Ltd. (SHA: 600867)

Market Cap	15.02B
Revenue (ttm)	2.45B
Net Income (ttm)	452.54M
Shares Out	1.98B
EPS (ttm)	0.23
PE Ratio	32.30
Forward PE	16.30
Dividend	0.25 (3.30%)
Ex-Dividend Date	May 23, 2024

Volume	12,794,900
Open	7.73
Previous Close	7.72
Day's Range	7.53 - 7.80
52-Week Range	7.35 - 12.73
Beta	0.21
Analysts	n/a
Price Target	n/a
Earnings Date	Oct 25, 2024

About Tonghua Dongbao Pharmaceutical

Tonghua Dongbao Pharmaceutical Co., Ltd. researches and develops, manufactures, and sells pharmaceutical for the treatment of diabetes, endocrine, and cardiovascular and cerebrovascular diseases products in China. The company operates through Pharmaceutical Industry; Building Materials Industry; and Real Estate Industry segments. It offers human insulin raw materials and injection, insulin glargine raw materials and injection, insulin aspart API and injection, Zhennaoning capsules, and diabetes-related medical devices. Further, it provides insu...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 1985
• Employees: 3,196
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 600867

Financial Performance

In 2023, 600867's revenue was 3.08 billion, an increase of 10.69% compared to the previous year's 2.78 billion. Earnings were 1.17 billion, a decrease of -26.17%.